Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 DeFi Kingdoms DeFi Kingdoms +1,091.73%
#4 Black Phoenix Black Phoenix +335.47%
#5 aPriori aPriori +115.91%
#6 Bedrock Bedrock +71.96%
#7 Cysic Cysic +43.64%
#8 Prom Prom +41.94%
#9 COTI COTI +40.84%
#10 Playnance Playnance +34.32%
Coin of the day
Wrapped One Wrapped One
Settings
Language
ENGLISH
Currency
USD
Theme
Roche Holding AG Roche Holding AG

Roche Holding AG

RO
Rank in Stocks #40
Roche Holding AG is a global healthcare enterprise with dual focuses:... Roche Holding AG is a global healthcare enterprise with dual focuses: pharmaceuticals and diagnostics. The company maintains a significant presence in numerous countries, including its home base in Switzerland, alongside Germany, the United States, Austria, the Netherlands, the United Kingdom, France, Belgium, and various other international markets. Its pharmaceutical segment develops and supplies treatments for a wide spectrum of medical conditions, encompassing oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments, as well as specific therapies for anemia, dermatology, hemophilia, inflammatory and autoimmune conditions, and transplant patients. On the diagnostic front, Roche provides in vitro tests designed to identify various diseases like cancer, diabetes, COVID-19, hepatitis, and human papillomavirus, in addition to supplying crucial diagnostic instruments and reagents. The company was founded in Basel, Switzerland, in 1896.
Share Price
$481.73
Market Cap
$377.65B
Change (1 day)
-0.96%
Change (1 year)
50.07%
Country
CH
Trade Roche Holding AG (RO)

Category

Healthcare
P/S ratio for Roche Holding AG (RO)
P/S ratio as of February 2026 TTM: 4.66
According to Roche Holding AG latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.66. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Roche Holding AG from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
14.97 221.37%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
6.31 35.42%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
7.06 51.47%
US
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
4.90 5.26%
US
Novartis AG Novartis AG
Novartis AG
NOVN.SW
5.52 18.51%
CH